Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

T-794: a MAO-A inhibitor with antidepressant activity

April 20, 1998

Phase I data reported on CoCensys' ganaxolone tablet formulation

April 17, 1998

Allelix gets go-ahead to start U.K. trials for antimigraine drug

April 17, 1998

OGS and Pfizer to collaborate on Alzheimer's disease research

April 17, 1998

Ampligen to be evaluated in U.S. phase III trials for chronic fatigue syndrome

April 17, 1998

Novel dopaminergic compounds in the pipeline at ADIR

April 17, 1998

Another H3 antagonist in the pipeline at Gliatech

April 16, 1998

DuPont Merck presents a novel CRF-R1 antagonist for anxiety and depression

April 16, 1998

Meiji Seika presents 5-HT7 antagonist DR-4004

April 16, 1998

Kynurenine 3-monooxygenase inhibitors under study at P&U as neuroprotectants

April 16, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...